Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

US FDA Grants Approval For Reckitt Benckiser's Suboxone Sublingual Film

RELATED NEWS
Trade RB.L now with 

Reckitt Benckiser Pharmaceuticals Ltd (RB.L) Monday announced that the U.S. Food and Drug Administration, or the FDA, has granted approval for 4 mg dose and 12 mg dose of Suboxone sublingual film.

Suboxone sublingual film is indicated for maintenance treatment of opioid dependence, also known as prescription opioid painkiller and heroin addiction, a growing epidemic in the United States.

Opioid dependence is a chronic and progressive medical condition caused in part by the changes in the chemistry of the brain that can result from regular opioid drug use. Dependence on opioids has been defined as a chronic (long-term) brain disease by the World Health Organization and the National Institute on Drug Abuse. Once opioid dependence develops, it is a chronic condition that left untreated can be fatal.

The pharmaceutical company further added that it has developed the 4 mg and 12 mg strengths in an ongoing effort to help mitigate the risk of unintentional multi-dose pediatric exposure, which is a major public health concern associated with medications.

Click here to receive FREE breaking news email alerts for Reckitt Benckiser Group PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Here is a quick summary of the earnings reported after the bell on Nov 19. Keurig Green Mountain, Inc. (GMCR) reported net income for the fourth quarter of $141.1 million or $0.86 per share, compared to $127.0 million or $0.83 per share for the year-ago quarter. Excluding items, adjusted net... Women's apparel retailer L Brands, Inc. said Wednesday that its third quarter profit rose 43% from last year, as sales increased 7%. The company's quarterly earnings per share also came in above analysts' expectations. At the same time, the company forecasts fourth quarter earnings below analysts' current consensus estimate, but once again raised its full year earnings outlook. PetSmart, Inc. said Tuesday after the markets closed that its third quarter profit remained essentially flat with last year, as higher costs and expenses offset a 2.6% increase in sales. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly sales.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.